NYSE:HAE stands out as a growth opportunity that won't break the bank.

Our stock screener has spotted HAEMONETICS CORP/MASS (NYSE:HAE) as a growth stock which is not overvalued. NYSE:HAE is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Unpacking NYSE:HAE's Growth Rating

To evaluate a stock's growth potential, ChartMill utilizes a Growth Rating on a scale of 0 to 10. This comprehensive assessment considers various growth aspects, including historical and estimated EPS and revenue growth. NYSE:HAE has achieved a 7 out of 10:

• The Earnings Per Share has grown by an impressive 31.35% over the past year.
• The Earnings Per Share has been growing by 10.74% on average over the past years. This is quite good.
• HAE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.01%.
• Based on estimates for the next years, HAE will show a very strong growth in Earnings Per Share. The EPS will grow by 21.40% on average per year.
• The Revenue is expected to grow by 10.74% on average over the next years. This is quite good.
• The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
• The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

Deciphering NYSE:HAE's Valuation Rating

ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NYSE:HAE, the assigned 6 reflects its valuation:

• Based on the Price/Earnings ratio, HAE is valued cheaply inside the industry as 83.42% of the companies are valued more expensively.
• The average S&P500 Price/Earnings ratio is at 29.19. HAE is valued slightly cheaper when compared to this.
• Based on the Price/Forward Earnings ratio, HAE is valued cheaply inside the industry as 82.89% of the companies are valued more expensively.
• HAE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. HAE is cheaper than 83.42% of the companies in the same industry.
• Based on the Price/Free Cash Flow ratio, HAE is valued cheaper than 82.35% of the companies in the same industry.
• HAE has an outstanding profitability rating, which may justify a higher PE ratio.
• HAE's earnings are expected to grow with 16.87% in the coming years. This may justify a more expensive valuation.

Health Analysis for NYSE:HAE

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NYSE:HAE has earned a 5 out of 10:

• HAE has an Altman-Z score of 3.62. This indicates that HAE is financially healthy and has little risk of bankruptcy at the moment.
• HAE has a Altman-Z score of 3.62. This is in the better half of the industry: HAE outperforms 67.91% of its industry peers.
• HAE has a Debt to FCF ratio of 7.00. This is in the better half of the industry: HAE outperforms 76.47% of its industry peers.
• HAE has a Current Ratio of 2.56. This indicates that HAE is financially healthy and has no problem in meeting its short term obligations.

Profitability Insights: NYSE:HAE

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NYSE:HAE, the assigned 9 is noteworthy for profitability:

• Looking at the Return On Assets, with a value of 5.35%, HAE belongs to the top of the industry, outperforming 83.96% of the companies in the same industry.
• With an excellent Return On Equity value of 12.24%, HAE belongs to the best of the industry, outperforming 87.70% of the companies in the same industry.
• HAE has a Return On Invested Capital of 8.55%. This is amongst the best in the industry. HAE outperforms 88.24% of its industry peers.
• The 3 year average ROIC (7.51%) for HAE is below the current ROIC(8.55%), indicating increased profibility in the last year.
• HAE has a better Profit Margin (8.98%) than 82.35% of its industry peers.
• In the last couple of years the Profit Margin of HAE has grown nicely.
• Looking at the Operating Margin, with a value of 15.57%, HAE belongs to the top of the industry, outperforming 86.10% of the companies in the same industry.
• HAE's Operating Margin has improved in the last couple of years.
• HAE's Gross Margin has improved in the last couple of years.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Our latest full fundamental report of HAE contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.